CR Sanjiu and KPC report strong preliminary 2024 financial results

China Resources Pharmaceutical Group (HKEX: 3320) announced preliminary unaudited financial information for two of its key subsidiaries, CR Sanjiu Medical & Pharmaceutical Co., Ltd. ("CR Sanjiu") and KPC Pharmaceuticals, Inc ("KPC"), for the year ended December 31, 2024. CR Sanjiu reported total operating revenue of RMB 27.617 billion, an 11.63% increase year-over-year, with total profit up by 22.40% to RMB 4.596 billion. Net profit attributable to shareholders reached RMB 3.369 billion, an 18.10% increase. Meanwhile, KPC, in which China Resources indirectly holds a 28.05% equity interest, reported operating revenue of RMB 8.401 billion, a 9.07% increase. Net profit attributable to shareholders of the listed company increased by 19.86% to RMB 648.0813 million, with basic earnings per share at RMB 0.86. Both companies noted these figures are preliminary and subject to final audit. The announcements emphasize that strategic direction and focus on innovation, particularly in the silver health sector for KPC, contributed to the positive results. China Resources notes that these results do not represent the whole Group's financial status. The reports have advised caution in dealing with shares of the company.